CryoCell International Inc (CCEL)vsJohnson & Johnson (JNJ)
CCEL
CryoCell International Inc
$4.15
0.00%
HEALTHCARE · Cap: $39.10M
JNJ
Johnson & Johnson
$270.47
+1.25%
HEALTHCARE · Cap: $682.52B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 319032% more annual revenue ($99.33B vs $31.13M). JNJ leads profitability with a 16.2% profit margin vs -6.3%. CCEL appears more attractively valued with a PEG of 1.34. JNJ earns a higher WallStSmart Score of 54/100 (C-).
CCEL
Hold47
out of 100
Grade: D+
JNJ
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+33.5%
Fair Value
$5.02
Current Price
$4.15
$0.87 discount
Margin of Safety
-84.0%
Fair Value
$145.14
Current Price
$270.47
$125.33 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 129 in profit
Earnings expanding 75.1% YoY
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 26.6%
Generating 6.4B in free cash flow
Areas to Watch
0.0% revenue growth
Smaller company, higher risk/reward
Operating margin of 0.6%
Distress zone — elevated risk
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Earnings declined 95.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : CCEL
The strongest argument for CCEL centers on Return on Equity, EPS Growth, Debt/Equity. PEG of 1.34 suggests the stock is reasonably priced for its growth.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 26.6%.
Bear Case : CCEL
The primary concerns for CCEL are Revenue Growth, Market Cap, Operating Margin.
Bear Case : JNJ
The primary concerns for JNJ are Piotroski F-Score, PEG Ratio, P/E Ratio. A P/E of 43.0x leaves little room for execution misses.
Key Dynamics to Monitor
CCEL profiles as a turnaround stock while JNJ is a mature play — different risk/reward profiles.
CCEL carries more volatility with a beta of 0.55 — expect wider price swings.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (54/100 vs 47/100), backed by strong 16.2% margins. CCEL offers better value entry with a 33.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CryoCell International Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Cryo-Cell International, Inc. is dedicated to cell processing and cryogenic cell storage with a focus on collecting and preserving umbilical cord blood stem cells for family use. The company is headquartered in Oldsmar, Florida.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?